The lack of appropriate pharmacological C/EBPδ‐targeting compounds precludes further preclinical assessment of C/EBPδ as treatment modality in cancer and the actual clinical implications of C/EBPδ re‐expression remain elusive. The gene discussed is CEBPD; the disease is cancer.